Voyager Therapeutics Files 8-K
Ticker: VYGR · Form: 8-K · Filed: Mar 13, 2024 · CIK: 1640266
Sentiment: neutral
Topics: 8-k, regulatory-filing, financials
TL;DR
Voyager Therapeutics filed an 8-K on Feb 29, 2024, mostly for financial docs.
AI Summary
Voyager Therapeutics, Inc. filed an 8-K on March 13, 2024, reporting events as of February 29, 2024. The filing primarily concerns financial statements and exhibits, with no specific material events detailed in the provided text.
Why It Matters
This filing indicates that Voyager Therapeutics, Inc. is providing updated financial statements and exhibits to the SEC, which is a standard regulatory requirement.
Risk Assessment
Risk Level: low — The filing appears to be routine and does not disclose any new material risks or significant events.
Key Numbers
- 001-37625 — SEC File Number (Voyager Therapeutics's SEC filing identifier.)
- 02421 — ZIP Code (The ZIP code for Voyager Therapeutics's principal executive offices.)
Key Players & Entities
- Voyager Therapeutics, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- Lexington, Massachusetts (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on 'Other Events' and to provide 'Financial Statements and Exhibits' as of February 29, 2024.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on February 29, 2024.
What is the company's principal executive office address?
The company's principal executive office is located at 75 Hayden Avenue, Lexington, Massachusetts, 02421.
What is Voyager Therapeutics, Inc.'s IRS Employer Identification Number?
Voyager Therapeutics, Inc.'s IRS Employer Identification Number is 46-3003182.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
Filing Stats: 1,214 words · 5 min read · ~4 pages · Grade level 10.1 · Accepted 2024-03-13 07:03:51
Key Financial Figures
- $0.001 — ge on which registered Common Stock, $0.001 par value VYGR Nasdaq Global Select
- $485,000 — led to receive an annual base salary of $485,000. He is also eligible to receive an annu
Filing Documents
- tm247944d1_8k.htm (8-K) — 31KB
- tm247944d1_ex10-1.htm (EX-10.1) — 83KB
- 0001104659-24-033726.txt ( ) — 304KB
- vygr-20240229.xsd (EX-101.SCH) — 3KB
- vygr-20240229_lab.xml (EX-101.LAB) — 33KB
- vygr-20240229_pre.xml (EX-101.PRE) — 22KB
- tm247944d1_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. Appointment of Toby Ferguson, M.D., Ph.D. as Chief Medical Officer On February 29, 2024, Voyager Therapeutics, Inc. (the "Company") and Toby Ferguson, M.D., Ph.D. entered into an employment agreement (the "Employment Agreement"), pursuant to which Dr. Ferguson agreed to serve as the Chief Medical Officer of the Company, with the first date of employment to commence on March 25, 2024 (the "Commencement Date"). Dr. Ferguson, age 54, previously served in positions of increasing responsibility at Biogen Inc. ("Biogen") from October 2013 to February 2024, culminating in his service as Vice President, Head of Neuromuscular Development Unit from February 2020 to February 2024. Dr. Ferguson also served as Executive Medical Director from July 2019 to February 2020, Senior Medical Director from May 2018 to July 2019, and other medical director roles from October 2013 to May 2018. Prior to joining Biogen, Dr. Ferguson was Assistant Professor of Neurology at Shriners Pediatric Research Center and Temple University School of Medicine. Dr. Ferguson received his B.S. from the University of Florida and his M.D. and Ph.D. from the University of Florida College of Medicine. Dr. Ferguson has no family relationship with any of the executive officers or directors of the Company or any person nominated or chosen by the Company to become a director or executive officer of the Company. There are no transactions in which Dr. Ferguson has an interest requiring disclosure under Item 404(a) of Regulation S-K. The Employment Agreement provides for Dr. Ferguson's at-will employment as Chief Medical Officer. Pursuant to the Employment Agreement, Dr. Ferguson is entitled to receive an annual base salary of $485,000. He is also eligible to receive an annual cash bonus, determined by and payable at the sole discretion of the board of directors of the Company (the "Board"), at a target level of 40% of his annual base salary then in effect. In accordance with the Employ
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Employment Agreement, by and between Voyager Therapeutics, Inc. and Toby Ferguson, M.D., Ph.D., dated as of February 29, 2024. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 13, 2024 VOYAGER THERAPEUTICS, INC. By: /s/ Alfred Sandrock, M.D., Ph.D. Alfred Sandrock, M.D., Ph.D. Chief Executive Officer, President, and Director (Principal Executive Officer)